#USA #oncology #Sydney #Kazia Therapeutics #NDL2

Kazia Therapeutics to Host Virtual Event on December 2, 2026

Kazia Therapeutics Limited (NASDAQ: KZIA), a pioneering biotechnology company dedicated to oncology, is set to host an engaging virtual event on December 2, 2026, at 4 PM ET. This event will provide attendees with an in-depth overview of NDL2, Kazia's innovative nuclear PD-L1 protein degrader, which is designed to combat immunotherapy resistance in advanced cancers, specifically targeting metastatic breast cancer and colorectal cancer.

NDL2 marks a significant advancement in the realm of targeted protein degradation, a cutting-edge therapeutic category currently lacking any known nuclear PD-L1 protein degraders in clinical development. The upcoming online session will delve into the scientific journey of NDL2, detailing its development from the initial concept to the pre-IND phase, highlighting its promise in redefining cancer immunotherapy strategies.

The event will be spearheaded by Kazia's management team, who will present detailed insights regarding NDL2's development process. This includes rigorous molecular optimization aimed at enhancing its effectiveness in restoring the immune system’s natural ability to fight tumor cells. By selectively degrading the nuclear PD-L1 protein associated with cancer cells, NDL2 endeavors to restore the body’s intrinsic anti-tumor immune response, thereby addressing one of the significant challenges faced by current immunotherapy treatments.

Understanding the role of PD-L1 is crucial, as it has been shown to assist cancer cells in evading immune detection, leading to treatment resistance. Kazia's approach utilizes targeted protein degradation (TPD) principles to effectively dismantle the disease-associated proteins that contribute to cancer progression. This strategy could very well represent a leap forward, potentially transforming standard practices in cancer therapy.

Following the presentation, a live question-and-answer session will give attendees the opportunity to engage directly with Kazia's team and gain further clarification on aspects of the research and its implications moving forward. Interested participants can register for the event via Kazia’s official website, where a replay will also be made available after the live session.

About Kazia Therapeutics

Kazia Therapeutics Limited stands at the forefront of oncological advancement with an emphasis on creating therapies that selectively reprogram cancer biology, aim to reinvigorate anti-tumor immunity, and effectively overcome existing treatment resistances. Leading its portfolio is paxalisib, an innovative drug that has made significant strides in treating various cancers, including those affecting the brain and metastatic forms of breast and colorectal cancers.

Paxalisib holds multiple designations from the U.S. FDA, highlighting its potential benefits, especially for glioblastoma and other critical conditions. Kazia is not only dedicated to advancing paxalisib but is also nurturing two landmark preclinical programs: NDL2, focusing on overcoming immunotherapy resistance, and MSETC, a SETDB1 inhibitor aimed at restoring immune signaling in treatment-resistant tumors.

In addition, Kazia is refining EVT801, a VEGFR-3 inhibitor, which showcases the company’s commitment to developing a diverse array of therapeutic options in oncology. For more information, please visit Kazia's official website and follow their updates on social media platforms.

Looking Ahead

As the landscape of cancer treatment continues to evolve, Kazia Therapeutics remains poised to lead research and development, potentially offering groundbreaking solutions that can change patient outcomes. With the NDL2 program, the company aims for not just improvements in existing cancer therapies but breakthroughs that redefine the paradigms of cancer treatment itself. Don’t miss this opportunity to learn more about these game-changing developments during the upcoming virtual event.